NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









CREATE Medicines

CREATE Medicines

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://createmedicines.com/

Last Round

Series B

May 14, 2026

Total Funding Raised

$245M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

CREATE Medicines is a clinical-stage biotechnology company that pioneers in vivo multi-immune programming to deliver scalable, repeat-dose, off-the-shelf immunotherapies for cancer, autoimmunity, and fibrosis.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

in vivo immune programmingmRNA-LNP platformin vivo CAR therapyoff-the-shelf immunotherapyin vivo cell therapyCAR-T therapymRNA therapiescancer immunotherapyautoimmune disease therapyLNP deliveryRNA therapeuticsChimeric Antigen ReceptorCARsolid tumor therapyclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

CREATE Medicines Comps

Public and private peers based on sector, stage, and business model.

CREATE Medicines comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

CREATE Medicines Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMay 14, 2026
Series A ExtensionMay 18, 2023
Series AJan 6, 2021

CREATE Medicines Investors

Notable investors and investment history

CREATE Medicines investors
InvestorRounds
Newpath PartnersSeries A Extension, Series A, Series B
ARCH Venture PartnersSeries A Extension, Series B
Hatteras Venture PartnersSeries A, Series A Extension, Series B
Alexandria Venture InvestmentsSeries A, Series A Extension, Series B
8VCSeries A, Series A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 14, 2026

    $122M round led by ARCH Venture Partners, Hatteras Venture Partners, and Newpath Partners.

  • May 18, 2023

    $73M round led by Hatteras Venture Partners.

CREATE Medicines Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

CREATE Medicines Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about CREATE Medicines's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Year Founded2019
Last FundingMay 14, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.